Compare Gilead Sciences, Inc. (GILD) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Liberty Global Ltd Class C — how do they compare? Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B), while Liberty Global Ltd Class C trades at $10.14 (market cap $3.48B). The key difference: Gilead Sciences, Inc. is far larger — about 48.4× Liberty Global Ltd Class C's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals.
| GILD | LBTYK | |
|---|---|---|
Market Cap | $168.35B | $3.48B |
Sector | Health | Technology |
52-Week High | $155.80 | $12.67 |
52-Week Low | $110.56 | $9.59 |
Enterprise Value | $191.42B | $10.13B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
LBTYK trades at $10.13, up 1.4% on the day, amid a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses, while full-year 2025 showed a net loss of $7.14B despite $4.88B revenue. Positive cash flow trends and the upcoming Ziggo Group spin-off in 2027 are key developments, with analyst sentiment leaning bullish with 69% buy ratings.
The outlook hinges on execution of asset monetizations and the Ziggo listing, offering upside from a discounted valuation, but high losses and competitive pressures pose significant risks. Investors should weigh the sum-of-parts opportunity against persistent profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
